Benzinga | Nov 4, 2021 09:24AM EDT

Editas Medicine To Present Data Demonstrating Progress Towards Transformative Gene Editing Medicines For The Treatment Of Hemoglobinopathies And Cancer At The ASH Annual Meeting And Exposition

EDIT-301 preclinical data support differentiated approach to develop a transformative medicine for people living with transfusion-dependent beta thalassemia

Preclinical data demonstrating proprietary CRISPR/Cas12a multiplexed editing of iPSCs enhances iNK tumor killing ability, supporting promise as a potential therapeutic approach for solid tumors